Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CD3 bispecific antibody true-killer combo

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 09, 2022 1:48pm

180 Views

Post# 35162211

RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

J&J's Talquetamab, had been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) in June 2022 for hard-to-treat multiple myeloma.

The FDA awards breakthrough therapy designation to accelerate the development of investigational treatments for serious or life-threatening conditions. It is based on preliminary clinical evidence showing a therapy’s improvement on at least one clinically significant goal compared with existing treatments.

Overall response rates (ORR) for Talquetamab were 70% (405 mcg/kg group) and 64% (800 mcg/kg group), with 57% and 52%, respectively, achieving a very good partial response or better rate. The median time to the first confirmed response was about one month for both groups.

https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-talquetamab-for-relapsed-refractory-myeloma

<< Previous

Bullboard Posts

Next >>

The deep connection between mining and First Nations in Canada